10月19日，Summit Therapeutics PLC盘中上涨5.23%，报15.395美元/股，成交额1473.64万美元。
消息面上，公司宣布与合作方康方生物启动Ivonescimab用于既往未经治疗的晚期透明细胞肾细胞癌二期研究，并已在美国和中国开启临床试验中心。
该研究计划入组约100名患者，旨在评估多种以Ivonescimab为基础的治疗方案，包括联合疗法。此前公司已获得阿斯利康20亿美元战略股权投资，资金与合作资源的落地也强化了核心肿瘤管线推进预期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.